American Academy of Pediatrics: Consider palivizumab for atypical interseason respiratory syncytial virus
Diabetes drug’s new weight loss formula fuels cost-benefit debate
12 August 2021Adoptive cell therapy plus checkpoint inhibitors show promise in non-small cell lung cancer
12 August 2021American Academy of Pediatrics: Consider palivizumab for atypical interseason respiratory syncytial virus
(HealthDay)—Palivizumab, which is usually considered for use to decrease the risk for hospitalization in selected infants at increased risk for severe respiratory syncytial virus (RSV) disease during the typical season, should be considered for use during the current atypical interseasonal spread, according to guidance published by the American Academy of Pediatrics (AAP).
